The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 346:1091-1092 April 4, 2002 Number 14
NextNext

Treatment of Acute Hepatitis C with Interferon Alfa-2b

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Jaeckel and colleagues (Nov. 15 issue)1 report that treatment of acute hepatitis C virus (HCV) infection with interferon alfa-2b prevents chronic infection. Their conclusion is based on the finding that in 42 of 43 patients who could be evaluated, HCV RNA in serum was undetectable 24 weeks after the end of treatment with interferon alfa-2b. To measure HCV RNA in serum, the authors used the Cobas Amplicor HCV C monitor, version 2.0 (Roche Diagnostics, Mannheim, Germany). This assay has a lower limit of detection of 600 IU per milliliter, not 600 copies per milliliter, as stated in . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.